BCTX — BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
- Exchange: NASDAQ
- Employees: 16
- Website: https://www.briacell.com
Latest SEC filings for BCTX
- 8-K — 2026-06-26
- 10-Q — 2026-06-09
- 8-K — 2026-06-03
- 424B5 — 2026-06-02
- 8-K — 2026-03-31
- 10-Q — 2026-03-10
- 8-K — 2026-03-09
- 8-K — 2026-02-20
Educational tool only — not investment advice.